Preclinical safety study of a combined therapeutic bone wound dressing for osteoarticular regeneration by Keller, Laetitia et al.
ARTICLE
Preclinical safety study of a combined therapeutic
bone wound dressing for osteoarticular
regeneration
Laetitia Keller1,2,11, Luc Pijnenburg1,2,11, Ysia Idoux-Gillet1,2,11, Fabien Bornert1,2, Laila Benameur3,
Maryam Tabrizian 3,4, Pierrick Auvray5, Philippe Rosset6, Rosa María Gonzalo-Daganzo7,
Enrique Gómez Barrena8, Luca Gentile 1,2,9,10 & Nadia Benkirane-Jessel1,2
The extended life expectancy and the raise of accidental trauma call for an increase of
osteoarticular surgical procedures. Arthroplasty, the main clinical option to treat osteoarti-
cular lesions, has limitations and drawbacks. In this manuscript, we test the preclinical safety
of the innovative implant ARTiCAR for the treatment of osteoarticular lesions. Thanks to
the combination of two advanced therapy medicinal products, a polymeric nanofibrous bone
wound dressing and bone marrow-derived mesenchymal stem cells, the ARTiCAR promotes
both subchondral bone and cartilage regeneration. In this work, the ARTiCAR shows 1) the
feasibility in treating osteochondral defects in a large animal model, 2) the possibility to
monitor non-invasively the healing process and 3) the overall safety in two animal models
under GLP preclinical standards. Our data indicate the preclinical safety of ARTiCAR
according to the international regulatory guidelines; the ARTiCAR could therefore undergo
phase I clinical trial.
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Regeneration of osteochondral defects represents a majorchallenge, especially considering the aging of the population.The surgical procedures currently applied (bone graft,
mosaicplasty, micro-fracture, articular prosthesis, therapeutic
implant), are invasive and/or painful for the patient, with limited
efficacy and side effects. Lesions of the femoral condyles, for
example, are a common side effect that could have serious con-
sequences1. A 2002 study found that ≥60% of patients undergoing
arthroscopy showed osteochondral defects2; in more than half of
the cases, such a lesion was classified as grade 3 or higher, according
to the International Cartilage Repair Society (ICRS) scale. Osteo-
chondral defects do not heal properly and, even when treated
(e.g. by Pridie’s marrow stimulation or by mosaicplasty treatment)
consistently led to osteoarthritis (OA)3,4. This inevitably has a high
impact on the public health system, with the direct costs of the
treatment, but it also has repercussions on the general economy
(social costs and loss of economic production), setting the overall
costs of the disease between 0.25 and 1% of a country’s GDP5,6.
The unique properties of the cartilage (multilayered cell structure,
different extracellular matrix composition and fibril orientation)
make it difficult to repair. Surgical techniques like micro-fracture,
mosaicplasty, osteoarticular transplantation or autologous chon-
drocytes implant may allow a partial functional recovery, but are
mostly aimed to relieve the pain and prevent the lesion to spread7.
Besides their variable outcome8 and intrinsic limitations9,10 none of
the afore-mentioned techniques was shown to restore the hyaline
articular surface11, justifying the search for alternatives to promote
osteoarticular regeneration (OAR). Recently, autologous chon-
drocytes pre-cultured on a membrane of mammalian collagen12–15,
were used to fill articular focal lesions and promote cartilage
regeneration. However, when performed on subchondral bone, they
showed site morbidity and fibrocartilage formation16, leading to a
dysfunctional repair. To overcome these limitations, mesenchymal
stem cell (MSCs)-based therapies emerged, which employ auto-
logous bone marrow-derived MSCs to increase the efficiency of
OAR17–20. A combination of biomaterials, stem cells and active
molecules are therefore needed to promote an effective tissue
repair and to achieve a functional recovery of the articulation21,22.
Recently, we proposed the ARTiCAR (ARTicular CArtilage and
subchondRal bone implant) combined Advanced Therapy Medicinal
Products (ATMPs) for personalized OAR (Fig. 1a, b). The implant is
made of a nanofibrous wound dressing (FDA-approved resorbable
polymeric Poly-ε-caprolactone)23–27 and autologous bone marrow-
derived MSCs27–29 (Fig. 1a). The wound dressing is nano-
functionalized with nanoreservoirs, for cell contact-dependent deliv-
ery of physiological concentrations of bone morphogenetic factor 2
(BMP2). The nanoreservoirs technology enabled to reduce the dose
of BMP2 to physiological levels, making it locally and sustainably
available, and reducing the adverse effects of its massive release, e.g.
from soaked collagen sponges currently used in the clinic30–32.
In this work, we test the safety of the ARTiCAR combined
ATMPs in two different animal models. Moreover, we assess
the feasibility of non-invasive monitoring of the healing process
in sheep, via MRI. The results of the toxicity and biodistribution
tests, run accordingly to the international regulatory guidelines
for cell therapies and medical devices33–37 and Good Laboratory
Practice (GLP)38, prove the biosafety of the ARTiCAR combined
ATMPs, which can therefore be used in phase I clinical trials as a
ready-to-use, flexible implant to address both cartilage and sub-
chondral bone regeneration in OA patients.
Results
Cytotoxicity of the NanoM1-BMP2 wound dressing in vitro.
The nanofibrous PCL wound dressing component (NanoM1-
BMP2; Fig. 1a) of the ARTiCAR combined ATMPs was tested for
cytotoxicity on MRC-5 fetal lung fibroblasts in vitro. Cells were
seeded in the presence of the NanoM1-BMP2 wound dressing
and compared to positive (polyurethane film; RM-A) and nega-
tive (high density polyethylene film; RM-C) controls. Different
sizes of both the NanoM1-BMP2 membrane and the control films
were tested in the range of 1-20 mm2. Cell density and mor-
phology were qualitatively evaluated by bright field microscopy.
Cells cultured in the presence of RM-A started to detach already
after 24 h (Fig. 2a–e). One the contrary, cells cultured in the
presence of the NanoM1-BMP2 scaffold did not show any mor-
phological abnormalities (Fig. 2f–j), as they did those cultured in
the presence of RM-C films (Fig. 2k–o). Next, we assessed the
viability of the MRC-5 cells in the 3 conditions tested, using
the WST-1 live/dead cell assay. Both RM-A and NanoM1-BMP2
showed a decrease in cell viability over 24 h that was directly
proportional to the size of the membrane used, as the interpolated
trend lines indicated (solid black lines in Fig. 2p–r). However, in
the presence of 20 mm2 RM-A, the cell viability reduced to 72 ±
5% compared to t0 (Fig. 2p, p ≤ 0.05), while in the presence of
a fragment of NanoM1-BMP2 of the same size, the cell viability
reduced to 97 ± 5% (Fig. 2q). No significant reduction of the cell
number was also observed in the presence of the negative control
film (Fig. 2r). These results indicate that the NanoM1-BMP2 is
not toxic to MRC-5 cells in vitro.
Acute toxicity after the implant of the ARTiCAR in nude rats.
The acute toxicity of the ARTiCAR was evaluated in vivo in
nude rats, and compared to the non active part of the implant
(hydrogel without hMSCs) as a vehicle. Clinical, hematological
and biochemical parameters were evaluated. The biodistribution
and the persistence of the transplanted cells were also assessed.
Briefly, ARTiCAR combined ATMPs (group 1) or vehicles (group
2) were implanted into femoral defects in nude rats. Ventricular
blood was taken before the animals were euthanised, 7 days post
implant, and femurs were collected for histopathology analysis.
Neither the ARTiCAR combined ATMPs, nor the vehicle trig-
gered any significant effect on the body weight, either in female or
male rats, over a period on 90 days following the implant
(Fig. 3a). Hematological parameters (Fig. 3b) showed no sig-
nificant differences among the 4 groups of animals (group 1 male,
group 1 female, group 2 male, group 2 female). Biochemical
parameters were also assessed (Fig. 3c). Female rats in Group
1 showed significantly higher plasmatic concentrations of both
Alanine aminotransferase (ALAT; 17.0 ± 2.0 U/l vs. 13.2 ± 1.6 U/l
for group 1 and 2, respectively; p ≤ 0.05) and Calcium (91.74 ±
1.02 mg/l vs. 88.46 ± 0.91 mg/l for group 1 and 2, respectively; p ≤
0.05) than those in group 2. These differences were not associated
with any additional symptoms and, altogether, the analysis of the
hematological and biochemical parameters considered did not
show any clinically relevant differences between ARTiCAR-
treated animals and the control group. The femur-tibia joints
were also collected and subject to histological analysis. Both the
ARTiCAR and the vehicle induced comparable levels of inflam-
matory response at the implant site (delimited by asterisks in 3d,
e), compatible with the bone healing process of the induced bone
defect (Fig. 3d, e). Eventually, the biodistribution of the human
MSCs at day 90 post implant was also assessed, using qPCR for
detecting human DNA. Signal from hMSCs DNA was never
detected above the threshold level, except in the testis of one male
rat in group 1. The migration of the PCR product on 2.5%
agarose gel confirmed the specificity of the amplification product.
Taken together, clinical, hematological and biochemical data
suggest that the ARTiCAR implant did not induce any clinically
relevant symptoms; the inflammatory response detected from the
histological analysis of the implant site revealed no differences
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with the control group, strongly indicating the safety of the
ARTiCAR implant for the treatment of bone defects.
Intra-articular implant of the ARTiCAR in sheep. To further
confirm the safety of the ARTiCAR combined ATMPs, and to
assess the feasibility of its usage in large animals, osteoarticular
defects were induced in femoral condyles of adult sheep and were
either left unfilled (no-treatment control: NT) of filled with the
ARTiCAR implant or with an autograft (AG), as for supplemental
table 1. The healing process was monitored non-invasively by
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Fig. 1 Composite advanced therapy medicinal product (ATMP) developed for the osteoarticular regeneration (OAR) of cartilage focal lesions. a The
ARTiCAR is a composite ATMP that combines an FDA-approved synthetic wound dressing and a living therapeutic made of autologous mesenchymal stem
cells (MSCs), embedded in alginate/hyaluronic acid hydrogel. The wound dressing, named NanoM1-BMP2 is made of nanofibrous poly-ε-caprolactone
nano-functionalized with Bone morphogenetic protein 2 and aims at subchondral bone regeneration. The cellular hydrogel aims at articular cartilage
regeneration. The NanoM1-BMP2 was tested for cytotoxicity in vitro (step 1); the whole ARTiCAR was tested for acute toxicity, biodistribution and
persistence in an osteochondral defect nude rat model (step 2) and for feasibility, safety, and non-invasive monitoring of the procedure (step 3) in a sheep
intra-articular model. b The ARTiCAR aims at the simultaneous regeneration of both the articular cartilage and the subchondral bone in a one-step surgical
procedure. After harvesting MSCs from patient’s bone marrow, the NanoM1-BMP2 is applied in contact with the injured subchondral bone; afterwards,
the MSCs mixed with the hydrogel is applied to fill the defect
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means of magnetic resonance imaging (MRI) at 0, 12 and
26 weeks (Fig. 4a–c). After either 12 or 26 weeks from implant,
sheep were euthanized and the femur-tibia joints were explanted
and scanned via micro-computing tomography (micro-CT;
Fig. 4d); a 3D surface rendering of the joint was also built from
2D section images (Fig. 4e). The explanted joints were macro-
scopically scored according to the ICRS score system as follows:
grade I= normal cartilage, grade II= nearly normal, grade III=
abnormal cartilage and grade IV= severely abnormal cartilage
(Fig. 4f). Eventually, the explants were stained in a solution
of safranin o–fast green and examined histologically (Fig. 4g).
The following parameters were taken into consideration within
the repaired tissue and scored according to ICRS II score
system39: subchondral bone abnormalities/marrow fibrosis, tissue
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Fig. 2 In vitro evaluation of the NanoM1-BMP2 wound dressing cytotoxicity. MRC-5 cell line was cultured in the presence of Polyurethane film, (RM-A;
a–e), NanoM1-BMP2 wound dressing (f–j) or high density polyethylene film (RM-C; k–q). Five sizes (20, 16, 9, 4, 1 mm²) of membranes were used. Cells
were inspected for morphological changes over a 3 day period. Proliferation/viability was assessed via WST-1 assay (p–n) at 24 h (C.Ris Pharma, CRO,
France). Error bars represent standard deviation. Scale bar: 100 µm
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10165-5
4 NATURE COMMUNICATIONS |         (2019) 10:2156 | https://doi.org/10.1038/s41467-019-10165-5 | www.nature.com/naturecommunications
morphology, cell morphology, basal integration, formation of
a tidemark, vascularization, overall assessment and mid/deep
zone assessment (supplemental table 2). In general, a correct
subchondral bone formation, a proper osteochondral remodeling
zone and a good integration between graft and host tissues were
observed within the induced bone defect 26 weeks after treatment
in all the experimental groups considered (Fig. 4g, h). Interest-
ingly, 12 weeks post implant, the ARTiCAR-treated defects
showed reduced vascularization (66 ± 16%), poorer quality of the
subchondral bone (25 ± 24%) and reduced tidemark (29 ± 34%)
(Fig. 4h, left panels). These scores were aligned to the NT group
(80 ± 14%; 54 ± 30%; 44 ± 30%, respectively), but significantly
different to the AG group (100 ± 0%, p ≤ 0.05; 88 ± 6%, p ≤ 0.05;
80 ± 16%; p ≤ 0.1, respectively). However, the ARTiCAR group
showed a better vascularization (2.5 ± 0.5) and a higher degree of
fibrosis (2.75 ± 0.5) then the AG groups in the tissues adjacent to
the defect (p ≤ 0.1 for both parameters), but not a level of fibro-
cartilage formation as high as in the NT control (p ≤ 0.1 and p ≤
0.05 at 12 and 26 weeks post implant, respectively) (Fig. 4h, right
panels, black arrow in Fig. 4j). These results suggest that the
ARTiCAR might induce a low inflammatory response that in turn
triggers regeneration40, inducing subchondral bone formation
(yellow arrow in Fig. 4k–n) and promoting effective healing in the
long term. Moreover, at 26 weeks post implant, matrix staining,
surface/superficial assessment, mid/deep zone assessment and
overall assessment showed the highest scores for the ARTiCAR
group (supplemental table 2), and no polymorphonuclear cells,
infection, fibrinous exudates and fatty infiltrates were detected
in the tissue adjacent to the defect in both the ARTiCAR and
the AG groups (supplemental table 3), indicating that the
ARTiCAR combined ATMPs treatment has a safety over the long
term comparable to that of an autograft.
Discussion
The global cartilage repair/regeneration market is valued at USD
4.2 billion in 2016 and is expected to grow at a CAGR of 5.4%
during the 2014-2025 period, owing to the increased life expec-
tancy. Currently, the international standard treatment for OA is
total knee arthroplasty (TKA). Despite its rapidly increasing
utilization (77,000 patients/year younger than 55 years, in the
US), TKA is prone to complications, like a higher risk of infec-
tion, persistent knee pain, patellar resurfacing problems and
prosthetic fracture41. Once complications developed, the con-
sequences for the patients are severe, which is why 20% of the
patients who underwent TKA were unsatisfied abut the surgery
outcome42. In most cases, revisions were required within 2-5
years after the primary implant43. Regenerative nanomedicine
combines the use of biomaterials, nanotechnologies and cells to
offer better solutions to issues like OAR, where a complex
interface regeneration is required. In this work, we assessed the
feasibility, non-invasive monitoring and safety of the ARTiCAR
combined ATMPs. Similarly to other smart implantable scaffolds
that promote osteochondral differentiation44–46, the ARTiCAR
releases a bone promoting factor. However, thanks to our
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Fig. 3 clinical, hematological, biochemical and histopathology evaluation of the ARTiCAR safety in an osteochondral defect nude rat model. a Individual
body weight curves of five male (M1-M5) and five female (F1-F5) rats, after implant of the ARTiCAR ATMP. b, c Seven days after implantation, ventricular
blood of implanted rats was collected (group 1: ARTiCAR, group 2: hydrogel without hMSCs; (n= 20) and analyzed for hematological and biochemical
parameters. WBCs: white blood cells; RBCs: red blood cells; HGB: haemoglobin; HCT: hematocrits; MCV: mean corpuscular volume; PLT: platelets. Data are
presented as the mean ± SD. One-way ANOVA followed by the Bonferroni post-hoc test was performed for significance. A p value≤ 0.05 was considered
significant. (C.Ris Pharma, CRO, France). d, e Histological sections of the intra-articular implant site in nude rats with femoral bone/cartilage defect, 7 days
after surgery (n= 20) for group 1 (d) and 2 (e), at ×5 magnification. Comparable inflammatory responses involved in bone healing process and no
systemic changes were observed in both group. Asterisks represent the limits of the defect. Scale bar: 1 mm
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Fig. 4 Feasibility, non-invasive monitoring and safety evaluation of the ARTiCAR combined ATMPs implanted in sheep intra-articular defect model. a–e the
OAR process after ARTiCAR implant was monitored non-invasively by means of MRI immediately after surgery (a) and at 12 (b) and 26 (c) weeks post
implant. The extension of the bone defect (white asterisks) and the ongoing OAR (white arrowheads) are visible. Micro CT-scan (d) followed by 3D
surface rendering (e) were performed on freshly explanted joints. f The level of cartilage regeneration was macroscopically assessed based on ICSR score
system. g, h Whole explants were sectioned and stained with safranin o - fast green (blue: bone; red: cartilage), imaged at ×4 and stitched together (g) to
evaluate the OAR according to the ICRS II score system (g). Scale bar: 1 mm. ICRS II parameters were examined for ARTiCAR and the control groups
considered and analyzed by mean of two-way ANOVA followed by Bonferroni post hoc test (h). *= p≤ 0.1; **= p≤ 0.05. Dots represent individual scores,
bars represent mean scores and error bars represent standard errors. (i–n) Zones of osteochondral remodeling within the treated defects in animals
from AG (I,L), NT (j, m) and ARTiCAR (k, n) groups, either at 12 or 26 weeks post implant. Bone (white asterisks), cartilage (black asterisk), fibrocartilage
(black arrow) and subchondral bone (yellow arrow) are shown. Scale bar: 500 µm
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patented nanoreservoir technology that provide cell contact-
dependent gradual release, the total amount of BMP2 used in the
ARTiCAR is 10.000 times lower than that of BMP2-soaked col-
lagen membranes used in the clinic30, reducing both potential
inflammatory side effects (Fig. 3d; Fig. 4g, h, k, n) and the overall
costs of the procedure. Differently to other approaches where a
poor subchondral bone regeneration was achieved47,48, the
ARTiCAR address simultaneous regeneration of both the sub-
chondral bone and the cartilage24–27,29 (Fig. 4g, k, n), repre-
senting an innovative technology for promoting OAR in a
localized osteochondral defect. For cartilage regeneration, the
ARTiCAR incorporates MSCs. Human MSCs are currently used
in clinical trials for promoting OAR49–51, because of their trans-
differentiation potential coupled to immunomodulatory
effect52,53. In future clinical trials, the MSCs could be directly
harvested from patients, allowing for autologous transplantation.
In order to be transplanted in human, MSCs will undergo an
implemented quality control (supplemental table 4), and will be
used only if the minimum release criteria for this type of ATMP
are satisfied54. However, since tumorigenicity of MSCs is still
debated55,56, the biodistribution of hMSCs is a critical concern of
preclinical safety57,58. After the implant of ARTiCAR, traces of
hMSC DNA were found in the testes of one male nude rat, out of
40 implanted animals (Fig. 3c). Also, no tumor formation was
observed in the transplanted rats and sheep, neither at the
implant site, nor in the rest of the body. Altogether, these data
pinpoint the safety of the ARTiCAR implant in respect to the
tumorigenicity of the transplanted MSCs.
In summary, we showed the feasibility of the ARTiCAR
implant in a large animal model and the possibility to follow OAR
non-invasively, by mean of MRI (Fig. 4a–c). More importantly,
we showed the safety of the ARTiCAR, as no acute or long term
toxicity was detected, neither in nude rats (Fig. 3d), nor in sheep
(Fig. 4g, h, k, n). Therefore, the ARTiCAR can enter phase I
clinical trials as a treatment for osteochondral defects, with the
potential to be used also for other conditions, like tendon
degeneration and age-related degenerative musculoskeletal issues.
As such, the ARTiCAR could replace more invasive current
treatments, with the potential to impact 300.000 to 450.000
patients/year only in the US ($4-5 billion global market).
Methods
Study design. All the experiments in this study were planned and performed
according to the international regulatory guidelines33–37 for cell therapies and
medical devices. Good Laboratory Practice38 and Standard Operating Procedures
(SOPs) for all protocols were used. In vitro cytotoxicity assay was done according
to ISO 10993-5 (2009 and 2012) guidelines. Assessment of the OAR was done
in accordance to the ICRS II score system39.
Production of the nanofibrous compartment of the ARTiCAR. The nanofibrous
component of ARTiCAR was obtained via electrospinning of PCL, as previously
described24. Briefly, PCL (PURASORB®, PURAC, Corbion, Amsterdam, Nether-
lands) was dissolved in a 25% (wt/vol) dimethylformamide/dichloromethane
solution (3/2, v/v) and delivered at a constant rate of 1 ml/h to the EC-DIG
electrospinning device (IME Technologies, Eindhoven, Netherlands), set to at high
voltage (20 ± 3 kV). Following electrospinning, PCL membranes were kept in a
desiccator at 45 °C, to remove residual solvents, and sterilized by gamma irradia-
tions (25 kGy). Membranes were then dipped alternately in 200 μg/ml
BMP2 solution (rh-BMP2, Inductos, Medtronic, France) in 40 mM 4-
Morpholinoethanesulfonic acid (Sigma-Aldrich, Saint-Quentin Fallavier, France),
150 mM Sodium Chloride (Sigma-Aldrich), pH 5.5 (MES buffer) and 0.5 mg/ml
Chitosan (Protasan UP CL 113, Novamatrix, Sandvika, Norway), for 12 times. Each
bath was followed by three washes in MES buffer.
Production of the hydrogel compartment of the ARTiCAR. Twelve mg/ml
sodium alginate (Sigma-Aldrich) and 3 mg/ml hyaluronic acid (Lifecore Biome-
dical, Chaska, USA) were dissolved in 9 mg/ml Sodium Chloride (Sigma-Aldrich).
Prior to implant, the hydrogel was mixed with either human or sheep MSCs. After
the MSC/hydrogel compartment was applied to fill the defect, gelation was
achieved using 102 mM calcium chloride (Sigma-Aldrich).
Cell culture. Human lung fetal fibroblast MRC-5 cell line (ECACC, Sigma-
Aldrich) was cultured in 75 cm2-flasks with EMEM (Lonza, Levallois-Perret,
France) containing 10% Fetal Bovine Serum (Lonza), 2 mM Glutamine (Lonza)
and 1% Non Essential Amino Acids (Lonza), under 5% CO2 humidified atmo-
sphere at 37 °C. Cell culture was performed accordingly to ISO 10993-5:2009
guidelines. The presence of mycoplasma in culture media was tested according to
internal SOPs.
Cytotoxicity assessment in vitro. MRC5 cells were plated into 24-well plates. The
NanoM1-BMP2 wound dressing was tested side-by-side with polyurethane film
containing 0.1% zinc diethyldithiocarbamate (known for inducing cytotoxic effects;
Hatano Research Institute/Food and Drug Safety Center, Japan) and high density
polyethylene film (negative control; Hatano Research Institute). To assess cyto-
toxicity, pieces of different size (20, 16, 9, 4, 1 mm2) were placed in contact to the
cultured cells, when 70–80% confluence was reached. Cells were cultured in the
presence of the membranes for 3 days before being examined microscopically for
changes in the general morphology, presence of vacuolization, detachment, lysis
and membrane integrity, following the criteria for the qualitative evaluation of
cytotoxicity according to ISO 10993 guidelines, part 5 (2009) and part 12 (2012):
Class 0, no reactivity (no effects around or below sample); Class 1, slight reactivity
(few malformed or degenerated cells); Class 2, mild reactivity (small area of mal-
formed or degenerated cells below the sample); Class 3, moderate reactivity
(malformed or degenerated cells in an area larger than the size of the sample but
≤1 cm2); Class 4, severe reactivity (malformed or degenerated cells in an area larger
than the size of the sample but >1 cm2). A grade higher than 2 was considered as
cytotoxic.
Quantitative cell viability assay. As a quantitative measure of cytotoxicity, cell
viability was evaluated. At day 3, membranes were discarded, cells were washed
twice with PBS, fed with 1 ml culture medium and 100 µl/well of Cell Viability
Reagent WST-1 (Lonza) was added to each well, according to internal SOPs. The
cells were incubated for 3 h at 37 °C in 5% CO2, and 100 µl of supernatant were
transferred into a 96-well plate. Absorbance was measured at 450 and 620 nm in a
Multiskan EX device (Thermo Fisher Scientific, Graffenstaden, France). Data
analysis was performed with Ascent 2.6 (Thermo Fisher Scientific). Results were
expressed as percentage of viable cells in respect to a blank control. A decrease of
30% viability was considered as cytotoxic.
Experiments with animals. Animal experiments were performed according to
the ethical guidelines for animal experiments59. The protocols used, included in
the project “Toxicologie Réglementaire”, was authorized by the “Ministère de
l’Enseignement supérieur et de la Recherche” No. 01191.02. Seven-weeks-old rats
were maintained for at least 5 days in Specific Pathogen Free rooms (authorized
by the French Ministries of Agriculture and Research; agreement No. A35 288-1)
before the beginning of the study, according to internal SOPs, under controlled
conditions of temperature (22 ± 3 °C), humidity (50 ± 20%), photoperiod (12 h
light/12 h dark) and air exchange, according to internal SOPs. Animals were
housed in standard-size polycarbonate cages (with filter lid), and bedding was
replaced twice a week.
Intra-articular implant of ARTiCAR in nude rats. Evaluation of acute toxicity
in vivo was achieved via intra-articular implant of ARTiCAR in a model of induced
osteochondral defect in RH-Foxn1 rnu/rnu nude rats (Harlan, Gannat, France).
Briefly, sterile NanoM1-BMP2 were rinsed in sterile PBS and cut into quarters
(1.77 mm2) before implant. Subconfluent human bone marrow MSCs (Promocell,
Heidelberg, Germany) were washed and resuspended in hyaluronic acid/alginate
mixture, as previously published28,29, to a concentration of 3.0 × 107 cells/ml. Prior
to implant, rats were anesthetized with intraperitoneal injection of a solution of 70
mg/kg ketamine and 10 mg/kg xylazine. After shaving and disinfection of right
hind leg, round 1.5 mm osteochondral defects were induced with a short drill in the
patellar groove of the femur, in the midline of the femoral trochlea, until bleeding
of the subchondral bone (approx. 2 mm). The NanoM1-BMP2 membrane was
placed at the bottom of the defect, which was in turn filled with hMSCs/hydrogel
mix and gelled via drop-wise addition of 102 mM calcium chloride (Sigma-
Aldrich), over 5 min. These rats constituted experimental group 1 (ARTiCAR;
n= 20 rats; 10 males and 10 females; 3.5 µl of hydrogel containing 105,000 ± 10%
cells). Other rats were subject to the same procedure, but implanted with hydrogel
only (as vehicle) and constituted group 2 (n= 20 rats; 10 males and 10 females;
3.5 µl of hydrogel). After gelation, the articulation capsule was closed, muscle and
skin were sutured and the wound was thoroughly disinfected with povidone-iodine
solution. After surgery, rats were kept under observation for post-anesthesia
recovery. After recovery, 0.05–0.1 mg/kg buprenorphine was administered by
subcutaneous injection. Animals were allowed unrestricted movement for the
duration of the study (90 days). Rats were monitored daily for wound healing,
leg mobility, morbidity, mortality and evident sign of toxicity.
Blood analysis. At day 7 post implant, five male and five female fasted rats/group
(n= 20) were anesthetized with excess isoflurane and ventricular blood was
collected either in EDTA-containing tubes or in heparin-containing tubes, for
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hematological or biochemical analysis, respectively. Between day 7 and 90, the
remaining rats were observed and monitored twice a week for any loss of weight.
Haematocrit, haemoglobin concentration, erythrocyte count, leukocyte counts,
mean corpuscular volume and platelet count were determined in the blood samples
on the day of collection by impedance variation and photometry (MINDRAY BC
2800 hematology analyzer, 4M, France). For biochemistry evaluation, plasma
samples were prepared according to internal SOPs. Sodium, potassium, chloride,
calcium, inorganic phosphate, glucose, urea, creatinine, total bilirubin, total cho-
lesterol, triglycerides, aspartate aminotransferase (ASAT), alanine aminotransferase
(ALAT), total proteins, albumin, and albumin/globulin ratio were quantified
(Cobas Mira biochemistry analyzer, 4M, France).
Histopathology analysis of nude rats implants. Histopathology analysis was
conducted on the fasted animals used for blood test. Briefly, a macroscopic autopsy
was performed on freshly euthanized rats. Organs (treated knee, spleen, mesenteric
lymph nodes, liver, lungs with bronchi and bronchiole, kidneys and heart) were
macroscopically observed, explanted and collected. The right hind paw was sec-
tioned at the epiphyses of both femur and tibia to recover knee joints subject to
implant. Spleen, liver, kidneys and heart were weighed and preserved with the
other organs at room temperature in 4% formalin (Sigma-Aldrich) until histolo-
gical analyses. Organs were fixed in 4% paraformaldehyde, dehydrated, embedded
in paraffin, sectioned and examined for histopathology.
Tissue harvesting for human DNA qPCR. Ninety days post implant, five male
and five female rats/group (n= 20) were euthanized by exsanguination under
anesthesia. After a macroscopic autopsy organs (ovaries with oviducts, testes, brain,
treated knee, spleen, liver, kidneys, lungs, bone marrow, heart and the skin cov-
ering the treated knee joint) were weighed and collected for DNA extraction using
the NucleoBond AXG100 kit (Macherey Nagel, Hoerdt, France), following man-
ufacturer’s instructions. Briefly, all tissue samples except knee joints were homo-
genized in M-tubes (Miltenyi Biotec, Paris, France) containing buffer G2 on a
GentleMACS Dissociator (Miltenyi Biotec, Paris, France). Knee joints were
homogenized using Ultra-Turrax® dissociator instrument in buffer G2. Following
extraction, the DNA pellet was dissolved in molecular biology grade water, and
stored at 20 °C. Quantitative PCR (qPCR) with the iTaq Universal Probes Super-
mix (BioRad, Marnes-la-Coquette, France) was used to quantify human Alu
sequences with the TaqMan AluYB8 Probe (Thermo Fischer Scientific). Genomic
DNA from the different tissues of the implanted rats was amplified side-by-side
with DNA from control rats, spiked-in with variable amount of DNA from U87-
MG human cells (22, 7, 0.7 ng; 70, 7, 2.2, 0.7, 0.07 pg or no DNA), to build a
standard curve. Samples were run in triplicate for 35 cycles on a CFX System (Bio-
Rad). The limit of detection corresponded to the average signal from control rat
DNA not spiked-in with human DNA.
Harvesting of MSCs from sheep bone marrow. Four weeks (28 ± 2 days) prior to
interarticular surgery, adult sheep females (Rideau Arcott Hybrids strain) were
subject to bone marrow aspiration procedure. Briefly, animals were placed in
ventral recumbency and anesthetized with a mix of glycopyrrolate, xylazine and
ketamine administered intramuscularly (IM). An IV catheter was placed in the
appropriate vein. The larynx was sprayed with lidocaine and the animals were
intubated with an appropriate sized cuffed orotracheal tube. If intubation was not
possible under IM anesthesia, induction was performed using isoflurane in O2
(1–5%) or propofol intravenously. The sheep were then mechanically ventilated
with isoflurane in O2. The harvest site was disinfected and a needle was introduced
in the iliac crest. A sterile 10 mL syringe was filled with 1 mL of 5000 IU/mL
heparin and filled with ~8 mL of bone marrow. The syringe containing bone
marrow sample and heparin was sealed with an appropriate sterile cap for
mesenchymal stem cells isolation, characterization and preparation for the surgical
procedure.
Isolation and expansion of bone marrow-derived sheep MSCs. The MSCs
harvested from sheep iliac crest were isolated according to their adherence to cell
culture plastic. Bone marrow aspirates were first washed by addition of an equal
volume of phosphate buffer saline (PBS; Sigma-Aldrich, France) and centrifuged at
220×g for 5 min. The cell pellets were suspended in Dulbecco’s Modified Eagle
Medium (DMEM; Lonza, Germany) containing 10% heat-inactivated fetal bovine
serum (Gibco, Thermo Fisher Scientific, France), 50 U/mL of penicillin (Lonza,
Germany), 50 μg/mL of streptomycin (Lonza, Germany), 2.5 μg/mL Fungizone
(Lonza, Germany), and seeded in a T75 culture flasks, under standard cell culture
conditions. The following day, medium was discarded and attached cells were
gently washed up several times with PBS to remove non-adherent cells. Flasks were
then incubated for several days in DMEM, replaced every 72 h to promote emer-
gence of colonies from adherent cells. When cells finally reached sub-confluence,
they were sub-cultured until passage 2, when they were expanded for stemness
characterization.
Characterization of sheep MSCs. The MSCs were characterized according to
their ability to form colonies and to their multipotency. Colony-forming unit-
fibroblast (CFU-F) assays were performed in triplicates (n= 3) with two different
ranges of serial dilutions. After 14 days of culture, MSCs were rinsed with PBS, and
fixed with 4% (w/v) paraformaldehyde. The colonies were stained using hema-
toxylin/eosin (Sigma-Aldrich, France) and counted. The potential of isolated sheep
cells to undergo trilineage differentiation was demonstrated in vitro. For adipo-
genic differentiation, sheep cells were seeded at 2.1 × 104 cells/cm2 and cultured for
3 days with proliferation culture medium. After that, they were induced to dif-
ferentiate by means of 3 alternate adipogenic induction/maintenance cycles. For
each cycle, cells were cultured for 3 days in standard induction medium (Lonza,
PT-3004), followed by 3 days of culture in standard maintenance medium (Lonza,
PT-3004). After three cycles, cells were then cultured for 7 days with maintenance
medium, replaced every 72 h. Negative controls for adipogenic differentiation were
cultured in DMEM. After 28 days of culture, cells were rinsed with PBS, fixed in 4%
(w/v) paraformaldehyde, rinsed with 60% (v/v) isopropanol and finally stained
with 0.5% (w/v) Oil Red O solution to detect lipid vesicles. For chondrogenic
differentiation, sheep cells were seeded as a pellet at the density of 2.5 × 104 cells
and cultured in chondrogenic medium (Lonza, PT-3925) supplemented with 10 ng/
mL of TGF-β3 growth factor (Peprotech, France). Negative control for chondro-
genic differentiation were cultured in DMEM. After 28 days of culture, pellets were
rinsed with PBS, fixed in 4% (w/v) paraformaldehyde, and embedded in paraffin.
Paraffin sections were stained with Alcian Blue solution (Sigma-Aldrich, France) to
visualize glycosaminoglycans and with Fast Red solution (Sigma-Aldrich, France)
to visualize cells nuclei. For osteogenic differentiation, sheep cells were seeded at
2.1 × 104 cells/cm2 and cultured for 3 days in DMEM. After, they were cultured in
osteogenic medium (Lonza, PT-3002). Negative controls for the osteogenic dif-
ferentiation were cultured in DMEM. After 21 days of culture, cells were rinsed
with PBS, fixed with ice-cold 70% (v/v) ethanol and stained with Alizarin Red
solution (40 mM, pH 4.1; Sigma-Aldrich, France) to detect calcium deposits.
Immunophenotypic characterization of sheep MSCs. For cell surface markers
analyses, cells were treated with 0.5% (w/v) bovine serum albumin and double-
stained using monoclonal antibodies, including phycoerythrin (PE)-conjugated
mouse anti-human CD34 (BD Biosciences, Le-Pont-de-Claix, France) with fluor-
escein isothiocyanate (FITC)-conjugated mouse anti-human CD90 (Beckman
Coulter, Villepinte, France), PE-conjugated mouse anti-human CD166 (Beckman
Coulter, Villepinte, France) with FITC-conjugated mouse anti-human CD45
(Dako, Glostrup, Denmark), PE-conjugated mouse anti-human CD105 (Beckman
Coulter, Villepinte, France) with FITC-conjugated mouse anti-human CD44
(Beckman Coulter, Villepinte, France), and PE-conjugated mouse anti-human
CD73 (BD Biosciences, Le-Pont-de-Claix, France) with FITC-conjugated mouse
anti-human leukocyte antigen-antigen D related (HLA-DR) (Beckman Coulter,
Villepinte, France). Antibodies were used at a dilution of 1:10 (PE CD34, FITC
CD90, PE CD166, FITC CD44, PE CD105, FITC HLA-DR and PE CD73) or 1:20
(FITC CD45). Appropriate isotype-matched control antibodies named FITC or PE
mouse IgG1 (Dako, Glostrup, Denmark) were used in each analysis. Cells were
then examined by flow cytometry using a BD LSR II flow cytometer (Becton
Dickinson Biosciences, San Jose, California). Fluorescence intensity and percentage
of antigen positive cells were determined for each surface marker.
Induction of osteochondral defect in sheep. A total of 16 adult sheep underwent
surgical induction of osteochondral defect into the medial femoral condyle. Three
groups of sheep (ARTiCAR, AG control, NT control) were considered; each sheep
was implanted on either the proximal or distal part of the right or left condyle of
posterior legs (supplemental table 1). For surgery, the hind limb was flexed to a
position at which the medial condyle could be palpated under the skin. A 15 cm
medial parapatellar skin incision was performed. After blunt dissection of the
subcutaneous tissues, the fascia overlying the vastus medialis muscle was incised
just distal to the belly muscle with a small incision parallel to the muscle fibers and
the vastus was retracted proximally. Blunt dissection was used to expose the
periosteum down to the medial condyle of the femur. The joint capsule and
periosteum were incised just proximal to the origin of the medial collateral liga-
ment. Overlying soft tissues were removed from the bone only in the vicinity of the
drill holes. Holes were predrilled using a 6-mm drill bit to a depth of 3 mm, except
for the AG group, where the hole had a depth of 6 mm.
Intra-articular implant of ARTiCAR in sheep. Following the induction of the
defect, the NanoM1-BMP2 was placed, and the defect was filled with MSCs/
hydrogel mix (ARTiCAR combined ATMPs, n= 9). In the AG group (n= 10), a
bone sample of 6 mm of diameter and 6 mm deep was taken out from the condyle
and placed into the defect. In the NT group (n= 13) the defect was neither treated,
nor filled. Up to 5 mL 0.25% bupivacaine were infiltrated into the surgical site to
achieve local anesthesia and manage pain after surgery. The tissues were reposi-
tioned and closed layer-by-layer using appropriate sutures. Postoperative analgesia
and antibiotic therapy were performed, 5 mg/kg Excede (IM) was administered
during recovery from anesthesia, and 4 mg/kg Carprofen (IM) was administered
3 days after surgery.
Non-invasive monitoring of ARTiCAR via MRI. For the longitudinal analysis of
the knee repair, sheep were examined three times via MRI, immediately after
surgery, at 15 and 26 weeks, using a Magnetom Verio 3 T (Siemens). For the
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procedure, sheep were anesthetized with an intravenous injection of 0.05 mg/kg
xylazine and 5 mg/Kg ketamine and placed in dorsal decubitus. A total of six sites
of surgery were imaged for each group. Proton density-weighted, fat-saturated
sagittal sections of the acquisitions were analyzed using the Osirix open-source
software.
Three-dimensional micro-CT of explanted femoral condyles. For analysis of the
bone mineralization, sheep were anesthetized, weighed and euthanized by a lethal
injection of 540 mg/ml Euthanyl rapid IV bolus 26 weeks after surgery. Death was
confirmed and recorded by observation of asystole or ventricular fibrillation, either
on the electrocardiogram or by auscultation. Femoral condyle from were explanted
from euthanized sheep and imaged via 3D micro-CT (Quantum Fx mCT, Julien
Becker, ICS, IGBMC, Strasbourg, France). A total of six sites of surgery were
imaged for each group. Three-dimensional surface rendering was obtained from
micro-CT 2D images using the Osirix open-source software.
Histopathology analysis of implants in sheep. Treated femurs were removed
from euthanized animals and subject to macroscopic inspection of the articular
surface. The distal femoral epiphysis (with condyles) were individually identified
and collected in 10% neutral buffered formalin, after macroscopic examination.
Bone blocks were cut in two halves, by sawing in the middle of the sample along its
longitudinal axis. Sections were cut through the defect along its deeper axis, from
the bone surface to the end of the drill hole producing rectangular-shaped defect
half sections. Full-thickness femoral bone-cartilage defect sites underwent unde-
calcified bone preparation and were infiltrated with methyl methacrylate and
polymerized. A single 8 μm section spanning the entire width of the defect was cut
along the parasagittal plane from each medial femoral condyle. The sections were
stained with safranin o–fast green, for the staining of both cartilage and bone. The
femoral defect sites were carefully evaluated and scored according to the ICRS
histological score system39 (Supplemental table 2). Also, the tissue underneath and
adjacent to the defect was evaluated for a number of parameters (Supplemental
table 3) to assess safety and efficacy of the treatments.
Statistical analysis. Results from the WST1 assay were statistically evaluated using
one-way ANOVA followed by Tukey post hoc test on Prism 4.03 (GraphPad). A p
value ≤ 0.05 was considered significant. One-way ANOVA followed by Bonferroni
post-hoc test was used to compare hematological and biochemical parameters in
the blood tests, using Prism 4.03. A p value ≤ 0.05 was considered significant. Both
SigmaPlot (SYSTAT Software) and Prism 5.0 (GraphPad) were used to compare
the ICSR II scores from the in vivo experiments in sheep. Equal variance test and
normality tests were performed. Either one- (differences induced by treatment) or
two-way ANOVA (differences induced by both treatment and time) followed by
Bonferroni post hoc test were used to assess significant differences among the
continuous variables of the study groups. If either equal variance test or normality
test failed, a Kruskal–Wallis one-way ANOVA with Dunn’s correction was con-
ducted. A p value ≤ 0.1 was considered significant.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All the original data discussed in this work are available upon request
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